Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

NCT06747169 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Squamous Non-Small Cell Lung Cancer SqNSCLC

Interventions

DRUG: Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin

Sponsor

Jian-Guo Zhou, MD, PhD